All
All

What are you looking for?

All
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”
NR7812

Genetic variability of pro- and anti-inflammatory cytokines in pathogenesis of rheumatoid arthritis

Project goals

Assesment of genetic variability of genes in cytokine net in respect to rheumatoid arthritis and its intermediate phenotype, inclusive of the analysis of selected cytokines plasma levels. For detection of pholymorphisms in promoter and introne regions, PCR and RFLP methods will be used. New polymorphisms in regulatory regions of IL-8, IL-13 and IL-15 genes will be detected by heteroduplex analysis and SSCP. The protein levels of cytokines will be measured by enzyme-amplified chemiluminiscence and ELISAmethod. The "case-control" (association) study will be used to assess the relation between genotype and disease. The significance of the differences will be calculated by chi-square test and Fisher's exact test. Odds ratio (OR) with 95% confidence interval will be used to estimate the relative risks.

Keywords

rheumatoidarthritiscytokinegenepolymorphismprotein-levels

Public support

  • Provider

    Ministry of Health

  • Programme

    Branch programm of research of the Ministry of Health

  • Call for proposals

    VaV pro Ministerstvo zdravotnictví 1 (SMZ02004NR)

  • Main participants

  • Contest type

    VS - Public tender

  • Contract ID

Alternative language

  • Project name in Czech

    Genetická variabilita pro- a proti-zánětlivých cytokinů v patogenezi revmatoidní artritidy

  • Annotation in Czech

    Zhodnocení genetické variability genů cytokinové sítě vzhledem k revmatoidní artritidě a jejímu intermediárnímu fenotypu, včetně analýzy plazmatických hladin vybraných cytokinů. Metod PCR a RFLP bude využito ke stanovení promotorových a intronových polymorfismů. Nové polymorfismy budou v regulačních oblastech genů pro IL-8, IL-13 a IL-15 detekovány pomocí heteroduplexní analýzy a SSCP. Proteinové hladiny vybraných cytokinů budou hodnoceny pomocí enzymaticky zesílené chemiluminiscence a ELISA metody. K vyjádření vtahu mezi genotypy a onemocněním bude využita tzv. "case-control" studie (asociační studie - "případ-kontroly"). Významnost rozdílů bude hodnocena pomocí chi-square testu a Fisher exact testu. Odds ratio (OR) s 95% konfidenčním intervalem budevyužito ke stanovení relativního rizika ve vztahu k RA.

Scientific branches

  • R&D category

    NV - Nonindustrial research (Applied research excluded Industrial research)

  • CEP classification - main branch

    FE - Other fields of internal medicine

  • CEP - secondary branch

    EB - Genetics and molecular biology

  • CEP - another secondary branch

  • 10603 - Genetics and heredity (medical genetics to be 3)
    10604 - Reproductive biology (medical aspects to be 3)
    10605 - Developmental biology
    10608 - Biochemistry and molecular biology
    10609 - Biochemical research methods
    30101 - Human genetics
    30217 - Urology and nephrology
    30218 - General and internal medicine
    30219 - Gastroenterology and hepatology
    30220 - Andrology

Completed project evaluation

  • Provider evaluation

    V - Vynikající výsledky projektu (s mezinárodním významem atd.)

  • Project results evaluation

    The presence of GG genotype in promoter region of 308TNF alpha is associated with more erosive and severe RA. This was published in a journal with IF. Besides, the relations to polymorphism of gene for IL-13, IL-15 were described.

Solution timeline

  • Realization period - beginning

    Jan 1, 2004

  • Realization period - end

    Jan 1, 2006

  • Project status

    U - Finished project

  • Latest support payment

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP07-MZ0-NR-U/06:2

  • Data delivery date

    Aug 8, 2007

Finance

  • Total approved costs

    2,490 thou. CZK

  • Public financial support

    2,467 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    13 thou. CZK